Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 468

1.

Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.

Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.

Scand J Rheumatol. 2009;38(5):323-7. doi: 10.1080/03009740902946355.

PMID:
19585384
2.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
3.

Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.

Jois RN, Masding A, Somerville M, Gaffney K, Scott DG.

Rheumatology (Oxford). 2007 Jun;46(6):980-2. Epub 2007 Mar 23.

PMID:
17384180
4.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

PMID:
11961174
5.

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group.

Arthritis Rheum. 2006 Sep;54(9):2793-806.

6.

Rituximab therapy in rheumatoid arthritis in daily practice.

Assous N, Gossec L, Dieudé P, Meyer O, Dougados M, Kahan A, Allanore Y.

J Rheumatol. 2008 Jan;35(1):31-4. Epub 2007 Nov 15.

PMID:
18176989
7.

The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.

Aletaha D, Smolen JS.

Rheumatology (Oxford). 2002 Dec;41(12):1367-74.

PMID:
12468815
8.
9.

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM; DANCER Study Group.

Arthritis Rheum. 2006 May;54(5):1390-400.

10.

Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.

Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.

Semin Arthritis Rheum. 2007 Oct;37(2):99-111. Epub 2007 Mar 27.

PMID:
17391739
12.

Remission in rheumatoid arthritis: wishful thinking or clinical reality?

Sesin CA, Bingham CO 3rd.

Semin Arthritis Rheum. 2005 Dec;35(3):185-96.

PMID:
16325659
13.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.

Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

PMID:
21571731
14.

Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.

Narváez J, Díaz-Torné C, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.

Semin Arthritis Rheum. 2011 Dec;41(3):401-5. doi: 10.1016/j.semarthrit.2011.06.005. Epub 2011 Aug 20.

PMID:
21862107
15.

Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis.

McGonagle D, Tan AL, Madden J, Taylor L, Emery P.

Rheumatology (Oxford). 2008 Jun;47(6):865-7. doi: 10.1093/rheumatology/ken103. Epub 2008 Apr 4.

PMID:
18390581
16.

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.

Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F.

Arthritis Rheum. 2007 Dec;56(12):3896-908.

17.

Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.

Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.

Ann Rheum Dis. 2009 Oct;68(10):1547-52. doi: 10.1136/ard.2008.096982. Epub 2008 Oct 17.

PMID:
18930989
18.

Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.

Thurlings RM, Vos K, Gerlag DM, Tak PP.

Arthritis Rheum. 2008 Dec;58(12):3657-64. doi: 10.1002/art.24035.

19.

How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.

Matteson EL, Weyand CM, Fulbright JW, Christianson TJ, McClelland RL, Goronzy JJ.

Rheumatology (Oxford). 2004 May;43(5):619-25. Epub 2004 Feb 24. Erratum in: Rheumatology (Oxford). 2004 Aug;43(8):1065.

PMID:
14983105
20.

Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis.

Kvalvik AG, Lefsaker L, Dyvik S, Brun JG.

Joint Bone Spine. 2007 Dec;74(6):606-11. Epub 2007 Aug 9.

PMID:
17900958

Supplemental Content

Support Center